Blue Cross & Blue Shield of MississippiCommercial · Coverage · Medical Policy · MS · Infectious Disease, Critical Care, Emergency Medicine +2 moreMedium impact
Recarbrio (imipenem-cilastatin-relebactam)
Act
immediately
Effective date
Not stated in the notice
Identified
Jun 20, 2026
Summary
BCBS Mississippi has updated their policy stating that Recarbrio (imipenem-cilastatin-relebactam) is considered not medically necessary for all approved indications including hospital-acquired pneumonia, ventilator-associated pneumonia, complicated UTIs, and complicated intra-abdominal infections because other covered alternatives are available. The drug is also considered investigational for all other uses.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.
01Billing team must flag HCPCS code J0742 (Recarbrio injection) as not covered by BCBS Mississippi due to availability of other covered alternatives.
02Update billing system to alert providers that claims for J0742 will likely be denied.
03Providers should use alternative covered antibiotics for hospital-acquired pneumonia, ventilator-associated pneumonia, complicated UTIs, and complicated intra-abdominal infections.
Codes mentioned
J0742
Original notice
Recarbrio (imipenem-cilastatin-relebactam)
bcbsms.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.